On April 4, 2022 Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, reported that new preclinical data on the company’s transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, Vivace Therapeurtics, APR 4, 2022, View Source [SID1234611423]). Presented findings will highlight results of research evaluating the combination of VT3989 and osimertinib (Tagrisso), an epidermal growth factor receptor (EGFR) inhibitor, in preclinical EGFR mutant tumor models. Study data demonstrated strong synergistic activity for the treatment combination as compared to osimertinib alone, as evidenced by enhanced efficacy and delayed tumor regrowth. The AACR (Free AACR Whitepaper) conference is being held April 8-13, 2022, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vivace’s proprietary compounds inhibit palmitoylation of members of the TEAD protein family, including both covalent and non-covalent inhibitors. The company’s clinical candidate, VT3989, is currently in Phase 1 clinical trials. Pre-clinical research and development activities have demonstrated that the clinical candidate is active as a monotherapy against tumors that rely upon dysfunction of the Hippo pathway, and in combination with other anti-cancer therapies in additional tumor types.

Details of the company’s presentation at the AACR (Free AACR Whitepaper) conference are as follows:

Poster Presentation #5364:

Title: The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models
Presenting Author: Tracy Tang, Ph.D., vice president of biology, Vivace Therapeutics
Date/Time: Friday, April 8, 2022, 12:00 – 1:00 p.m. Central
Location: E-Poster Website